GlassScriptPhysician profile
Cameron R Dick
NPI 1194780767
$10,175.69
in general payments reported to CMS, 2019-2025
43 companies · $914 in 2025
The $914 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,450 · 2020: $1,358 · 2021: $1,770 · 2022: $2,134 · 2023: $1,586 · 2024: $963 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,464.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,464.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,133.65 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,031.91 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Electromed, INC. | $933.53 | 2019-2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $867.08 | 2019-2025 | Ofev, Jascayd |
| Insmed, INC. | $624.88 | 2019-2025 | Arikayce, Brinsupri |
| Philips North America LLC | $593.83 | 2019-2025 | (Di7) Home Pi Undivided, (7999) Src Undivided, Incourage Airway Clearance Therapy |
| United Therapeutics Corporation | $584.97 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Genzyme Corporation | $479.12 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $437.94 | 2019-2024 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $403.57 | 2020-2025 | Dupixent |
| Genentech USA, INC. | $317.84 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $248.93 | 2020-2025 | Glassia |
| Mylan Specialty L.P. | $212.21 | 2020-2024 | Yupelri |
| Advanced Respiratory, INC | $210.72 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $202.08 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $180.63 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Sandoz INC. | $179.88 | 2019-2022 | |
| Amgen INC. | $159.57 | 2022-2025 | Tezspire |
| Jazz Pharmaceuticals INC. | $145.29 | 2019-2021 | |
| Getinge USA Sales, LLC | $143.08 | 2022-2025 | Cardiohelp, Cardiohelp |
| Abbvie INC. | $128.79 | 2022-2024 | |
| Abiomed | $111.36 | 2023 | Impella |
| Grifols USA, LLC | $98.42 | 2019-2021 | |
| Verona Pharma, INC. | $84.69 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $74.90 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $70.66 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $66.55 | 2022-2024 | |
| Pulmonx Corporation | $63.30 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Merck Sharp & Dohme LLC | $42.24 | 2019-2020 | |
| Inspire Medical Systems, INC. | $40.07 | 2023-2025 | Inspire |
| Viatris Specialty LLC | $36.03 | 2025 | Yupelri |
| Livanova USA, INC. | $35.44 | 2023 | Lifesparc |
| Johnson & Johnson Health Care Systems INC. | $34.54 | 2023 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $34.29 | 2022 | |
| Zoll Respicardia, INC. | $23.93 | 2025 | Remede System |
| Allergan, INC. | $23.21 | 2019 | |
| Shire North American Group INC | $17.67 | 2019 | |
| Abbott Laboratories | $17.37 | 2022 | |
| Vapotherm INC | $17.37 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.20 | 2023 | |
| Inogen, INC. | $17.15 | 2022 | |
| Corcept Therapeutics | $15.21 | 2025 | Korlym |
| Gilead Sciences, INC. | $14.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Dick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.